EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

741

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

DEVICE: Optune® device
DRUG: Temozolomide
DRUG: Pembrolizumab
DRUG: Placebo

Sponsor

NovoCure GmbH

Collaborators

[object Object]